On 24 July 2009, orphan designation (EU/3/09/648) was granted by the European Commission to Clinuvel UK Limited, United Kingdom, for afamelanotide for the treatment of solar urticaria.
The sponsorship was transferred to Clinuvel Europe Limited, Ireland, in March 2019
Treatment of solar urticaria
|Orphan designation status||
|EU designation number||
|Date of designation||
Clinuvel Europe Limited
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: